PORTFOLIO
Pharmaceutical Research and Development
CKG Management facilitates collective investments in pharmaceutical research and development companies that are requiring seed money to continue pre clinical and clinical research. Additional investments may be made in these companies that continue to progress through clinical trials. CKG Management targets companies that have unique technology with a plan of selling the technology to a global strategic once it is validated. Below are a list of companies that CKG Management has a collective investment amongst its members:
CAGE Bio, currently a resident company at Johnson & Johnson Innovation JLBAS@ MBC BioLabs, is a clinical-stage startup exploiting its proprietary deep eutectic ionic liquid platform to develop novel products for dermatology, inflammation, and immunology.
Participated in the $7.2mm Series A Funding - June 2019
via Series CJV, LLC
Participated in the $15mm Series A Offering - October 2021
via Series C2JV, LLC.
Distributor investor capital returns due to a sale of a single asset -
October 2024
Nanoscope Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies to cure genetic diseases that cause vision impairment and blindness.
Participated in the $15mm Series A Funding - February 2020
via Series NTJV, LLC
Participated in the $30mm SAFE - September 2022
via Series NT2JV, LLC
Participated in the $30mm SAFE - October 2024
via Series NT3JV, LLC
OncoNano Medicine is developing a new class of products that exploit universal cancer and immune therapeutic targets to diagnose and treat cancer. Our product candidates are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery, and T cell activating immunotherapies.
Participated in the $50mm Series B Funding - October 2019
via Series OJV, LLC
Renibus Therapeutics is a biotech company dedicated to transforming the cardio-renal disease treatment paradigm by focusing on the prevention, treatment, and diagnostic testing of kidney disease. Each year, 9 million U.S. adults suffer from acute kidney injury (AKI), and today, 37 million U.S. adults are living with chronic kidney disease (CKD). As the most common complication of a number of surgical procedures, AKI occurs in approximately 30% of patients undergoing cardiac surgery. It is associated with a higher risk of mortality in both inpatient and outpatient settings, and progression to CKD within 24 months occurs in approximately 15-20% of patients who survive AKI.
Participated in the $11.3mm Series A Funding - November 2019
via Series R2JV, LLC.
Participated in the $15mm Series A Offering - November 2021
via Series R3JV, LLC.
Participated in the $72mm Series B Offering - August 2023
via R4JV, LLC.